NMR structure of the human oncofoetal fibronectin ED-B domain, a specific marker for angiogenesis

被引:52
|
作者
Fattorusso, R
Pellecchia, M
Viti, F
Neri, P
Neri, D
Wüthrich, K
机构
[1] ETH Honggerberg, Inst Mol Biol & Biophys, CH-8093 Zurich, Switzerland
[2] Univ Siena, Dipartimento Biol Mol, Sez Biochim, I-53100 Siena, Italy
关键词
angiogenesis marker; ED-B domain; fibronectin isoform; NMR;
D O I
10.1016/S0969-2126(99)80051-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: The process of angiogenesis (i.e. the formation of new blood vessels from pre-existing ones) is fundamental to physiological processes such as reproduction, development and repair, as well;Is to pathological conditions such as tumor progression, rheumathoid arthritis and ocular disorders. The oncofoetal ED-B domain, a specific marker of angiogenesis, consists of 91 amino acid residues that are inserted by alternative splicing into the fibronectin (FN) molecule. Results: The NMR structure of the ED-B domain is reported and reveals important differences from other FN type III domains. A comparison of the ED-B domain with the crystal structure of a four-domain FN fragment shows the novel features of ED-B to be located in loop regions that are buried at interdomain interfaces, and which therefore largely determine the global shape of the FN molecule. The negatively charged amino acids in this highly acidic protein are uniformly distributed over the molecular surface, with the sole exception of a solvent-exposed hydrophobic patch that represents a potential specific recognition site. Epitope mapping with 82 decapeptides that span the ED-B sequence revealed that three ED-B-specific monoclonal antibodies, which selectively target newly forming blood vessels in tumor-bearing mice, bind to adjacent regions on the ED-B surface. Conclusions: The NMR structure enables the identification of a large surface area of the ED-B domain that appears to be accessible in vivo, opening up new diagnostic and therapeutic opportunities. Furthermore, the mapping of specific monoclonal antibodies to the three-dimensional structure of the ED-B domain, and their use in angiogenesis inhibition experiments, provides a basis for further investigation of the role of the ED-B domain in the formation of new blood vessels.
引用
收藏
页码:381 / 390
页数:10
相关论文
共 50 条
  • [21] Expression of ED-B fibronectin in tissues from human hematologic malignancies.
    Sauer, Stefanie
    Hoffmann, Jens
    Menrad, Andreas
    Durkop, Horst
    Menssen, Hans D.
    BLOOD, 2006, 108 (11) : 156B - 156B
  • [22] EXPRESSION OF TENASCIN AND OF THE ED-B CONTAINING ONCOFETAL FIBRONECTIN ISOFORM IN HUMAN CANCER
    NICOLO, G
    SALVI, S
    OLIVERI, G
    BORSI, L
    CASTELLANI, P
    ZARDI, L
    CELL DIFFERENTIATION AND DEVELOPMENT, 1990, 32 (03): : 401 - 408
  • [23] DISTRIBUTION OF ED-A AND ED-B CONTAINING FIBRONECTIN ISOFORMS IN DUPUYTRENS DISEASE
    HALLIDAY, NL
    RAYAN, GM
    ZARDI, L
    TOMASEK, JJ
    JOURNAL OF HAND SURGERY-AMERICAN VOLUME, 1994, 19A (03): : 428 - 434
  • [24] The Angiogenesis Marker ED-B+ Fibronectin Isoform in Intracranial Meningiomas
    P. Castellani
    A. Dorcaratto
    A. Pau
    M. Nicola
    A. Siri
    B. Gasparetto
    L. Zardi
    G. Viale
    Acta Neurochirurgica, 2000, 142 : 277 - 282
  • [25] Specific expression of the ED-B containing fibronectin isoform by endothelial cells of growing tumor vessels
    Castellani, P
    Viale, G
    Dorcaratto, A
    Querze, G
    Allemanni, G
    Zardi, L
    Siri, A
    ANTIBODY IMMUNOCONJUGATES AND RADIOPHARMACEUTICALS, 1995, 8 (04): : 325 - 332
  • [26] ED-B fibronectin (ED-B) can be targeted using a novel single chain antibody conjugate and is associated with macrophage accumulation in atherosclerotic lesions
    Dietrich, Thore
    Perlitz, Christin
    Licha, Kai
    Stawowy, Philipp
    Atrott, Kirstin
    Tachezy, Michael
    Meyborg, Heike
    Stocker, Carolin
    Graefe, Michael
    Fleck, Eckart
    Schirner, Michael
    Graf, Kristof
    BASIC RESEARCH IN CARDIOLOGY, 2007, 102 (04) : 298 - 307
  • [27] Targeted ED-B fibronectin SPECT in vivo imaging in experimental atherosclerosis
    Dietrich, T.
    Berndorff, D.
    Heinrich, T.
    Hucko, T.
    Stepina, E.
    Hauff, P.
    Dinkelborg, L. M.
    Atrott, K.
    Giovannoni, L.
    Neri, D.
    Fleck, E.
    Graf, K.
    Menssen, H. D.
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 59 (02): : 228 - 237
  • [28] ED-B fibronectin in non-small cell lung carcinoma
    Khan, ZA
    Caurtero, J
    Barbin, YP
    Chan, BM
    Uniyal, S
    Chakrabarti, S
    EXPERIMENTAL LUNG RESEARCH, 2005, 31 (07) : 701 - 711
  • [29] ED-B Fibronectin Targeted In Vivo Imaging and Radiotherapy of Pancreatic Cancer
    Berndorff, D.
    Sieger, S.
    Rother, A.
    Wagner, K.
    Amthauer, H.
    Cyr, J. E.
    Dinkelborg, L. M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 : S47 - S48
  • [30] ED-B fibronectin (ED-B) can be targeted using a novel single chain antibody conjugate and is associated with macrophage accumulation in atherosclerotic lesions
    T. Dietrich*
    C. Perlitz*
    K. Licha
    P. Stawowy
    K. Atrott
    M. Tachezy
    H. Meyborg
    C. Stocker
    M. Gräfe
    E. Fleck
    M. Schirner
    K. Graf
    Basic Research in Cardiology, 2007, 102 : 298 - 307